Spin-offs

Omne possibile was founded in March 2021. The company focuses on realizing the potential of XNA technologies in modern biotechnology, relying on metabolic engineering and xenobiotic import strategies developed at the BPL.

MemoTherapeutics was founded in 2013. The company focuses on the clinical development of antibodies. The Bioprocess Laboratory developed the first generation of high throughput screening protocols employed by MemoTherapeutics for antibody discovery.

FGen was founded in 2012. The company operates as a custom research partner for the pharmaceutical and chemical industry. The startup technology of FGen is the nanoliter reactor platform for high throughput screening in gel-carriers originally developed by the Bioprocess Laboratory.